A novel mutation panel for predicting etoposide resistance in small-cell lung cancer

PURPOSE: Platinum-based chemotherapy, consisting of etoposide and cisplatin (EP), has been the cornerstone of therapy for extensive-stage small-cell lung cancer (ES-SCLC) for decades. Despite the marked initial sensitivity of SCLC to chemotherapy, EP regimens cannot avoid the emergence of drug resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Zhengang, Lin, Anqi, Li, Kun, Lin, Weiyin, Wang, Qiongyao, Wei, Ting, Zhu, Weiliang, Luo, Peng, Zhang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594009/
https://www.ncbi.nlm.nih.gov/pubmed/31417239
http://dx.doi.org/10.2147/DDDT.S205633

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594009/
https://www.ncbi.nlm.nih.gov/pubmed/31417239
http://dx.doi.org/10.2147/DDDT.S205633

Ejemplares similares